Clinical trial
Study in High Risk Patients Switched From Higher Doses of Other Statins to…
NCT00240344 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00240344 |
|---|---|
| Title | Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal |
| Official title | REALISTIC: Protocol for an Observational Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New EAS LDL-C Target Goal |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Hypercholesterolemia |
| Enrollment | 2,650 |
| Start date | Sep 1, 2004 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Oct 18, 2005 |
| Last update posted | Aug 30, 2011 |
| Countries | Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: